Regulatory FDA kicks off review of Roche’s Gazyva for wider lupus use PharmaphorumRoche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.RegulatoryImmunology & InflammationRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus. RegulatoryImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyNext: Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
